[{"id":"f04191d0-49ef-4557-a5c3-c47df0794683","acronym":"","url":"https://clinicaltrials.gov/study/NCT06782932","created_at":"2025-02-25T19:18:04.732Z","updated_at":"2025-02-25T19:18:04.732Z","phase":"Phase 1/2","brief_title":"Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer","source_id_and_acronym":"NCT06782932","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • balstilimab (AGEN2034) • AGEN2373 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • Hiltonol (poly-ICLC) • KRAS peptide vaccine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 04/01/2025","start_date":" 04/01/2025","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-01-20"},{"id":"de3b1a71-0b74-42e6-87b8-569689ad09da","acronym":"","url":"https://clinicaltrials.gov/study/NCT03153410","created_at":"2025-02-25T16:06:15.779Z","updated_at":"2025-02-25T16:06:15.779Z","phase":"Phase 1","brief_title":"Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas","source_id_and_acronym":"NCT03153410","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • LY3022855"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 09/27/2018","start_date":" 09/27/2018","primary_txt":" Primary completion: 03/09/2022","primary_completion_date":" 03/09/2022","study_txt":" Completion: 08/29/2023","study_completion_date":" 08/29/2023","last_update_posted":"2025-01-09"},{"id":"b2c9ef7d-2fb3-45a4-a86b-257c668139cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03767582","created_at":"2021-02-23T17:53:27.774Z","updated_at":"2025-02-25T14:27:51.862Z","phase":"Phase 1/2","brief_title":"Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.","source_id_and_acronym":"NCT03767582","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" TNFRSF9","pipe":"","alterations":" ","tags":["TNFRSF9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • BMS-813160 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells)"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 12/12/2019","start_date":" 12/12/2019","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-12-10"},{"id":"15ea0b15-7362-42f9-a5c9-83b6fa5b6dd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02451982","created_at":"2021-01-18T11:45:29.420Z","updated_at":"2025-02-25T14:35:37.102Z","phase":"Phase 2","brief_title":"Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas","source_id_and_acronym":"NCT02451982","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD8 • PD-1 • TNFRSF9 • GZMB • IL17A","pipe":"","alterations":" ","tags":["CD8 • PD-1 • TNFRSF9 • GZMB • IL17A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cyclophosphamide • BMS-986253 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • cyclophosphamide intravenous • urelumab (BMS-663513)"],"overall_status":"Recruiting","enrollment":" Enrollment 76","initiation":"Initiation: 03/28/2016","start_date":" 03/28/2016","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2024-12-06"},{"id":"971d9282-8be3-4d0b-a747-485b598d1a88","acronym":"","url":"https://clinicaltrials.gov/study/NCT03006302","created_at":"2024-01-03T19:17:30.474Z","updated_at":"2025-02-25T16:05:38.933Z","phase":"Phase 2","brief_title":"Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer","source_id_and_acronym":"NCT03006302","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" STAT6","pipe":"","alterations":" ","tags":["STAT6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • epacadostat (INCB024360) • CRS-207 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 01/31/2018","start_date":" 01/31/2018","primary_txt":" Primary completion: 08/22/2023","primary_completion_date":" 08/22/2023","study_txt":" Completion: 08/05/2024","study_completion_date":" 08/05/2024","last_update_posted":"2024-10-08"},{"id":"b40756a9-7d90-4abb-8054-b9366010a008","acronym":"","url":"https://clinicaltrials.gov/study/NCT01595321","created_at":"2021-01-29T07:03:06.836Z","updated_at":"2024-07-02T16:35:53.802Z","phase":"","brief_title":"Pancreatic Tumor Cell Vaccine (GVAX), Low Dose Cyclophosphamide, Fractionated Stereotactic Body Radiation Therapy (SBRT), and FOLFIRINOX Chemotherapy in Patients With Resected Adenocarcinoma of the Pancreas","source_id_and_acronym":"NCT01595321","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" MSLN","pipe":"","alterations":" ","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • cyclophosphamide • oxaliplatin • irinotecan • leucovorin calcium • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 10/29/2012","start_date":" 10/29/2012","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-03-08"},{"id":"5d5babd2-7c3c-4130-a0da-f4352113269f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02243371","created_at":"2021-01-18T10:31:41.476Z","updated_at":"2025-02-25T14:34:56.150Z","phase":"Phase 2","brief_title":"GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab","source_id_and_acronym":"NCT02243371","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cyclophosphamide • CRS-207 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 93","initiation":"Initiation: 01/02/2015","start_date":" 01/02/2015","primary_txt":" Primary completion: 07/21/2017","primary_completion_date":" 07/21/2017","study_txt":" Completion: 07/21/2017","study_completion_date":" 07/21/2017","last_update_posted":"2021-04-06"},{"id":"c725a546-35dd-4095-87fa-07754d08078f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01896869","created_at":"2021-01-18T08:31:41.063Z","updated_at":"2024-07-02T16:36:44.908Z","phase":"Phase 2","brief_title":"FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT01896869","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • 5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells)"],"overall_status":"Completed","enrollment":" Enrollment 83","initiation":"Initiation: 11/01/2013","start_date":" 11/01/2013","primary_txt":" Primary completion: 05/03/2019","primary_completion_date":" 05/03/2019","study_txt":" Completion: 05/03/2019","study_completion_date":" 05/03/2019","last_update_posted":"2020-05-19"},{"id":"79674bd5-a912-4c92-ba36-b09510f51cb9","acronym":"","url":"https://clinicaltrials.gov/study/NCT00727441","created_at":"2021-01-18T02:44:20.530Z","updated_at":"2024-07-02T16:36:49.564Z","phase":"Phase 2","brief_title":"Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery","source_id_and_acronym":"NCT00727441","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" MSLN • CD4 • FOXP3","pipe":"","alterations":" ","tags":["MSLN • CD4 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 87","initiation":"Initiation: 07/02/2008","start_date":" 07/02/2008","primary_txt":" Primary completion: 05/01/2015","primary_completion_date":" 05/01/2015","study_txt":" Completion: 02/01/2019","study_completion_date":" 02/01/2019","last_update_posted":"2020-02-25"}]